Cid:[email protected] (6d85f252 307c 4aa8 9572 1e74c9819283 00)
Drospirenone And Ethinyl Estradiol Kit
Product Images NDC 68462-733
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Drospirenone And Ethinyl Estradiol (NDC 68462-733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Cid:[email protected] (6d85f252 307c 4aa8 9572 1e74c9819283 01)
Blister
Carton (Carton)
This is a package of birth control pills with 21 active tablets and 7 inactive tablets, used for contraception. The pills contain drospirenone and ethinyl estradiol, and should be taken daily for 28 days per menstrual cycle. The package includes three individual units, each containing one blister of 28 tablets. It is manufactured by Glenmark Pharmaceuticals Limited, in Goa, India and distributed by Glenmark Pharmaceuticals Inc. in the USA. The packaging includes a warning to keep the medication out of reach of children and that it is not child-resistant. The drug does not protect against HIV infections and other sexually transmitted diseases.*
Figure 3
Figure1 (Figure1)
This text appears to be a list of different studies or analyses related to medical research, specifically focusing on hazard ratio, rate ratio, and odds ratio. It mentions studies from different countries such as Denmark and Germany, as well as studies being funded by the FDA. The text provides some information about the types of studies conducted, including prospective and retrospective cohort studies, case-control studies, and studies that only include non-fatal idiopathic cases. Additionally, there are some numerical figures at the end which could potentially relate to statistical results.*
Figure2 (Figure2)
The text is a figure showing the likelihood of developing a VTE (venous thromboembolism) in different scenarios. It includes data based on the number of women with a blood clot out of 10,000 Women Years (WY), and ranges from non-pregnant non-COC users to pregnant and postpartum women. The figure provides statistics on the probabilities of developing a VTE in these different situations.*
Drospirenone Structure (Image 03)
Drospirenone is a medication used in combination with ethinyl estradiol to prevent pregnancy. It is a synthetic hormone that can also be used to treat acne and premenstrual dysphoric disorder. It works by inhibiting ovulation and altering cervical and uterine lining, making it difficult for sperm to reach the uterus.*
Ethinyl Estradiol Structure (Image 04)
Img1 (Img1)
This text describes different levels of pregnancy rates among women based on the method of birth control used. It indicates that there are fewer than 1 pregnancy per 100 women in a year with an unspecified method of birth control. It also notes that using certain birth control methods such as implants, injections, intrauterine devices, birth control pills, skin patch or vaginal ring with hormones, and sterilization can result in pregnancy rates of 5 or fewer pregnancies per 100 women in a year. Using other methods such as diaphragm, spermicide, withdrawal, or having no birth control can result in pregnancy rates of 10-20 pregnancies per 100 women in a year. The text suggests various options for preventing pregnancy.*
Img3 (Img3)
This text presents ranges of blood clot occurrences in non-pregnant COC-users and non-COC users, as well as during pregnancy and postpartum (up to 12 weeks). The number of occurrences is given per 10,000 Women Years (WY). The data for pregnancy is based on the actual duration of pregnancy in the reference studies, with a rate range of 7 to 27 per 10,000 WY, assuming pregnancy duration is nine months.*
Pouch (Pouch)
This is a product description for Drospirenone and Ethinyl Estradiol Tablets, USP made by Glenmark Pharmaceuticals Limited. It is a birth control medication that comes in a blister pack of 28 tablets, with 21 light yellow to yellow tablets and 7 white to off-white tablets. It is intended to be taken once a day for 28 consecutive days per menstrual cycle. The medication should be stored between 20°C to 25°C (68°F to 77°F) and should be kept away from the reach of children. It is not intended to protect against HIV or other sexually transmitted diseases. Contact information for Glenmark Pharmaceuticals is provided for questions.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
